FDA approves Sylvant for rare Castleman's disease
The FDA approved Sylvant (siltuximab) to treat patients with multicentric Castleman’s disease (MCD), a rare disorder similar to lymphoma. MCD causes an abnormal overgrowth of immune cells in lymph nodes and related tissues in the body. Sylvant is marketed by Janssen Biotech in Horsham, Pa. April 23, 2014